Head-to-head evidence
GS101 vs Manfidokimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
GS101
Developed by Jiangsu Genscend Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07386743 (registry estimate)
Manfidokimab
Developed by Akeso
NCT06383468 · Phase 3 · status unknown
This Phase 3 trial randomly assigned adults with moderate-to-severe atopic dermatitis to manfidokimab (AK120) or placebo, both delivered by subcutaneous injection, under quadruple-blind conditions, with the proportion of patients achieving EASI-75 (75% improvement in eczema severity) at week 16 as the primary endpoint. No results have been posted, so this remains a well-designed, adequately sized, blinded, placebo-controlled trial whose findings are not yet known.
Next expected readout: July 2027 · NCT06767540 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GS101's landscape · Manfidokimab's landscape